WallStSmart

Boston Scientific Corp (BSX)vsiRhythm Technologies Inc (IRTC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Boston Scientific Corp generates 2444% more annual revenue ($21.00B vs $825.34M). BSX leads profitability with a 17.5% profit margin vs -1.7%. BSX earns a higher WallStSmart Score of 72/100 (B).

BSX

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 6.7Quality: 5.5
Piotroski: 5/9Altman Z: 1.78

IRTC

Avoid

32

out of 100

Grade: F

Growth: 7.3Profit: 3.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.28
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXOvervalued (-10.0%)

Margin of Safety

-10.0%

Fair Value

$39.07

Current Price

$42.98

$3.91 premium

UndervaluedFair: $39.07Overvalued

Intrinsic value data unavailable for IRTC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX6 strengths · Avg: 8.2/10
Market CapQuality
$62.29B9/10

Large-cap with strong market position

PEG RatioValuation
0.608/10

Growing faster than its price suggests

P/E RatioValuation
17.5x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

Free Cash FlowQuality
$1.28B8/10

Generating 1.3B in free cash flow

IRTC1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
20.1%8/10

Revenue surging 20.1% year-over-year

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

IRTC4 concerns · Avg: 3.0/10
Price/BookValuation
19.8x4/10

Trading at 19.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

Altman Z-ScoreHealth
0.282/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.

Bull Case : IRTC

The strongest argument for IRTC centers on Revenue Growth. Revenue growth of 20.1% demonstrates continued momentum.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : IRTC

The primary concerns for IRTC are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 3.91 is elevated, increasing financial risk.

Key Dynamics to Monitor

BSX profiles as a mature stock while IRTC is a growth play — different risk/reward profiles.

IRTC carries more volatility with a beta of 1.32 — expect wider price swings.

IRTC is growing revenue faster at 20.1% — sustainability is the question.

BSX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (72/100 vs 32/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

iRhythm Technologies Inc

HEALTHCARE · MEDICAL DEVICES · USA

iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.

Want to dig deeper into these stocks?